Pharmaxi LLC is a CRO launched in 2013 by two MDs who whose dream it was to build the best CRO in the world. The main idea was to make complex clinical trials easy for the client.
We are focused on the clinical trials of medical products, medical devices, and dietary supplements. Pharmaxi performs services in Poland, Ukraine and Eastern Europe. Currently, we have 34 employees on board, divided into several departments: Clinical Operations, Data Management, and Biometrics.
We work for big (Sanofi, AbbVie, Takeda) and small (Sankom, Peptigroup, Flyser) pharmaceutical and biotech companies from 21 European and North American countries.
Pharmaxi LLC is a client-oriented, flexible, innovative and cost-effective Contract Research Organization.
Pharmaxi LLC is focusing on the planning and management of the projects generating clinical evidence. We do clinical trials, postmarketing studies, and registries to collect clinical and performance data for medicines, medical devices, and IVD products. Technical documentation review and clinical evaluation plan/report are also developed by a dedicated team together with German consulting partners.
The Company is skilled at performing all the trial activities: from the study design negotiation to the creation of the final study report. You can rely upon us even if you have some specific tasks which are not covered by our in-house facilities (drug depot, logistics, insurance, and delivery services). These activities are delegated to trusted and fully-vetted subcontract companies. For more information about our services, please visit this page.
Over the years, projects have been completed in the fields of cardiology, endocrinology, gastroenterology, pulmonology, pediatrics, nephrology, gynecology, oncology, neurology, rheumatology and orphan diseases. It is also possible to conduct clinical trials in other therapeutic areas.
| Featured projects | Number of subjects | Number of sites |
|---|---|---|
| Chronic pancreatitis (randomized, double-blind, double-dummy) | 210 | 7 |
| Comparison of a new formulation of XXXX to XXXX in patients with dysfunctional uterine bleeding requiring endometrial ablation (randomized, single-blind). | 90 | 6 |
| Parallel group single-blind study to compare the pharmacokinetic profiles and pharmacodynamic response of a new depot formulation of XXXX to XXXXXX in ambulatory patients with advanced carcinoma of the prostate | 160 | 8 |
| A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus XXXX in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Hospitalized Adults | 110 | 6 |
| Phase II, Prospective, Multi-center, Randomized, Controlled, Two arms, double Blind Study to assess Efficacy and Safety of XXX Administered Concomitantly with the Standard of Care (SOC), compared to SOC treated control arm, in the prevention of post abdominal surgery incisional infection. | 120 | 9 |
| A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the antiviral efficacy and safety of XXXX in subjects with moderate Covid-19 in Standard of Care Setting | 540 | 17 |
| A phase III, multi-center, international, randomized, assessor-blind, parallel-arm study to evaluate the efficacy, safety, and tolerability of XXX in comparison to XXXX in relapsing-remitting multiple sclerosis (RRMS) patients | 125 | 6 |